TABLE 1.
Species, phenotype (no. of isolates tested), and antimicrobial agent | MIC range (μg/ml) | MIC90 (μg/ml) | % Susceptible (NCCLS susceptible breakpoint) |
---|---|---|---|
S. pneumoniae | |||
Penicillin susceptible (728) | |||
Penicillin | ≤0.03-0.06 | ≤0.03 | 100 (≤0.06) |
Amoxicillin-clavulanate | ≤0.015-0.25 | ≤0.015 | 100 (≤2) |
Cefuroxime | ≤0.015-0.25 | 0.03 | 100 (≤1) |
Ceftriaxone | ≤0.12-0.5 | ≤0.12 | 100 (≤1) |
Vancomycin | ≤0.06-0.5 | 0.25 | 100 (≤1) |
Erythromycin | ≤0.015->2 | 0.06 | 93.1 (≤0.25) |
Clindamycin | ≤0.25->1 | ≤0.25 | 98.1 (≤0.25) |
Levofloxacin | ≤0.25->8 | 1 | 99.3 (≤2) |
SXT | ≤0.06->4 | 1 | 89.3 (≤0.5) |
Quinupristin-dalfopristin | ≤0.12-2 | 0.5 | 99.0 (≤1) |
Linezolid | ≤0.25-2 | 1 | 100 (≤2) |
Daptomycin | ≤0.015-0.25 | 0.12 | (NA)a |
Penicillin intermediate (248) | |||
Penicillin | 0.12-1 | 1 | 0 |
Amoxicillin-clavulanate | ≤0.015-4 | 1 | 99.6 |
Cefuroxime | ≤0.015-2 | 0.5 | 98.8 |
Ceftriaxone | ≤0.12->4 | 4 | 31.0 |
Vancomycin | ≤0.06-0.25 | 0.25 | 100 |
Erythromycin | 0.03->2 | >2 | 35.5 |
Clindamycin | ≤0.25->1 | >1 | 79.8 |
Levofloxacin | ≤0.25->8 | 1 | 98.8 |
SXT | 0.12->4 | >4 | 33.9 |
Quinupristin-dalfopristin | ≤0.12-1 | 0.5 | 100 |
Linezolid | ≤0.25-1 | 1 | 100 |
Daptomycin | ≤0.015-0.5 | 0.25 | |
Penicillin resistant (187) | |||
Penicillin | 2->8 | 4 | 0 |
Amoxicillin-clavulanate | 0.25-8 | 8 | 46.0 |
Ceftriaxone | 0.25->4 | 4 | 81.8 |
Cefuroxime | 2->4 | >4 | 0 |
Vancomycin | ≤0.06-0.25 | 0.25 | 100 |
Erythromycin | 0.03->2 | >2 | 13.9 |
Clindamycin | ≤0.25->1 | >1 | 74.3 |
Levofloxacin | ≤0.25-8 | 1 | 98.4 |
SXT | 0.25->4 | >4 | 2.1 |
Quinupristin-dalfopristin | ≤0.12-1 | 0.5 | 100 |
Linezolid | 0.5-1 | 1 | 100 |
Daptomycin | ≤0.015-0.25 | 0.12 | |
S. pyogenes (484) | |||
Penicillin | ≤0.03-0.12 | ≤0.03 | 100 (≤0.12) |
Amoxicillin-clavulanate | ≤0.015-0.25 | ≤0.015 | (NA) |
Ceftriaxone | ≤0.015-0.25 | ≤0.015 | 100 (≤0.5) |
Cefuroxime | ≤0.12-0.5 | ≤0.12 | (NA) |
Vancomycin | ≤0.06-0.5 | 0.25 | 100 (≤1) |
Erythromycin | ≤0.015-<2 | 0.12 | 91.1 (≤0.25) |
Clindamycin | ≤0.25->1 | ≤0.25 | 98.6 (≤0.25) |
Levofloxacin | ≤0.25-8 | 0.5 | 99.8 (≤2) |
SXT | ≤0.06->4 | 0.25 | (NA) |
Quinupristin-dalfopristin | ≤0.12-1 | ≤0.12 | 100 (≤1) |
Linezolid | ≤0.25-2 | 1 | 100 (≤2) |
Daptomycin | ≤0.015-0.5 | 0.06 | (NA) |
S. agalactiae (273) | |||
Penicillin | ≤0.03-0.12 | 0.06 | 100 (≤0.12) |
Amoxicillin-clavulanate | ≤0.015-0.12 | 0.06 | (NA) |
Ceftriaxone | ≤0.015-0.12 | 0.06 | 100 (≤0.5) |
Cefuroxime | ≤0.12-0.5 | ≤0.12 | (NA) |
Vancomycin | 0.12-0.5 | 0.25 | 100 (≤1) |
Erythromycin | 0.03->2 | >2 | 72.2 (≤0.25) |
Clindamycin | ≤0.25->1 | >1 | 87.5 (≤0.25) |
Levofloxacin | ≤0.25->8 | 1 | 98.9 (≤2) |
SXT | ≤0.06-4 | 0.12 | (NA) |
Quinupristin-dalfopristin | ≤0.12-1 | 0.25 | 100 (≤1) |
Linezolid | 0.5-1 | 1 | 100 (≤2) |
Daptomycin | 0.03-0.5 | 0.25 | (NA) |
Viridans streptococci (369) | |||
Penicillin | ≤0.03-8 | 2 | 71.3 (≤0.12) |
Amoxicillin-clauvulanate | ≤0.015-16 | 2 | (NA) |
Ceftriaxone | ≤0.015->4 | 1 | 87.5 (≤1) |
Cefuroxime | ≤0.12->4 | 4 | (NA) |
Vancomycin | ≤0.06-2 | 0.5 | 99.7 (≤1) |
Erythromycin | ≤0.015->2 | >2 | 51.8 (≤0.25) |
Clindamycin | ≤0.25->1 | ≤0.25 | 93.8 (≤0.25) |
Levofloxacin | ≤0.25->8 | 1 | 97.6 (≤2) |
SXT | ≤0.06->4 | 2 | (NA) |
Quinupristin-dalfopristin | ≤0.12-2 | 1 | 99.5 (≤1) |
Linezolid | ≤0.25-2 | 1 | 100 (≤2) |
Daptomycin | ≤0.015-2 | 1 | (NA) |
S. aureus | |||
Oxacillin susceptible (713) | |||
Oxacillin | ≤0.06-2 | 0.5 | 100 (≤2) |
Vancomycin | ≤0.25-1 | 1 | 100 (≤4) |
Erythromycin | ≤0.12-16 | >16 | 34.6 (≤0.5) |
Clindamycin | 0.06->4 | 0.5 | 92.7 (≤0.5) |
Gentamicin | ≤0.06->16 | 1 | 97.2 (≤4) |
Teicoplanin | ≤0.12-16 | 0.5 | 99.9 (≤8) |
Ciprofloxacin | ≤0.03->8 | 2 | 89.3 (≤1) |
SXT | ≤0.25->4 | ≤0.25 | 96.9 (≤2) |
Quinupristin-dalfopristin | ≤0.06-0.5 | 0.25 | 100 (≤1) |
Linezolid | 0.5-4 | 4 | 100 (≤4) |
Daptomycin | 0.03-0.5 | 0.25 | (NA) |
Oxacillin resistant (305) | |||
Oxacillin | 4->8 | >8 | 0 |
Vancomycin | ≤0.25-2 | 1 | 100 |
Erythromycin | 0.5->16 | >16 | 2.6 |
Clindamycin | 0.06->4 | >4 | 36.4 |
Gentamicin | ≤0.06->16 | >16 | 79.3 |
Teicoplanin | ≤0.12-4 | 1 | 100 |
Ciprofloxacin | 0.06->8 | >8 | 12.5 |
SXT | ≤0.25->4 | >4 | 87.9 |
Quinupristin-dalfopristin | ≤0.06-1 | 0.5 | 100 |
Linezolid | ≤0.25-4 | 4 | 100 |
Daptomycin | 0.12-0.5 | 0.5 | |
Coagulase-negative staphylococci (1,126) | |||
Oxacillin | ≤0.06->8 | >8 | 31.6 (≤0.25) |
Vancomycin | ≤0.25-4 | 2 | 100 (≤4) |
Erythromycin | ≤0.12->16 | >16 | 28.2 (≤0.5) |
Clindamycin | ≤0.03->4 | >4 | 67.5 (≤0.5) |
Gentamicin | ≤0.06->16 | >16 | 71.4 (≤4) |
Teicoplanin | ≤0.12->32 | 8 | 96.0 (≤8) |
Ciprofloxacin | ≤0.03->8 | >8 | 53.1 (≤1) |
SXT | ≤0.25->4 | >4 | 61.5 (≤2) |
Quinupristin-dalfopristin | ≤0.06-4 | 0.5 | 99.5 (≤1) |
Linezolid | ≤0.25-4 | 2 | 100 (≤4) |
Daptomycin | ≤0.015-2 | 0.5 | (NA) |
E. faecium | |||
Vancomycin susceptible (147) | |||
Vancomycin | ≤0.5-4 | 1 | 100 (≤4) |
Ampicillin | ≤0.25-128 | 64 | 44.2 (≤8) |
Teicoplanin | ≤0.03-8 | 0.5 | 100 (≤8) |
Ciprofloxacin | ≤0.12->64 | >64 | 32.7 (≤1) |
Quinupristin-dalfopristin | ≤0.12-8 | 2 | 85.7 (≤1) |
Linezolid | ≤0.5-2 | 2 | 100 (≤2) |
Daptomycin | 0.06-8 | 4 | (NA) |
Vancomycin resistant (219) | |||
Vancomycin | 32->256 | >256 | 0 |
Ampicillin | 0.5->128 | 128 | 0.9 |
Teicoplanin | ≤0.03->64 | >64 | 14.2 |
Ciprofloxacin | 0.25->64 | >64 | 1.4 |
Quinupristin-dalfopristin | 0.25-2 | 1 | 97.3 |
Linezolid | 1-4 | 2 | 99.5 |
Daptomycin | 0.25-4 | 4 | |
E. faecalis | |||
Vancomycin susceptible (2,049) | |||
Vancomycin | ≤0.5-4 | 2 | 100 (≤4) |
Ampicillin | ≤0.25-8 | 1 | 100 (≤8) |
Teicoplanin | ≤0.03-1 | 0.12 | 100 (≤8) |
Ciprofloxacin | ≤0.12->64 | 64 | 59.3 (≤1) |
Quinupristin-dalfopristin | ≤0.12-32 | 8 | 3.9 (≤1) |
Linezolid | ≤0.5-2 | 2 | 100 (≤2) |
Daptomycin | 0.03-4 | 2 | (NA) |
Vancomycin resistant (40) | |||
Vancomycin | 32->256 | >256 | 0 |
Ampicillin | ≤0.25-2 | 2 | 100 |
Teicoplanin | ≤0.03->64 | >64 | 67.5 |
Ciprofloxacin | 0.5->64 | >64 | 7.5 |
Quinupristin-dalfopristin | ≤0.12-32 | 16 | 2.5 |
Linezolid | 1-2 | 2 | 100 |
Daptomycin | ≤0.015-2 | 2 | |
Other Enterococcus spp. (80) | |||
Vancomycin | ≤0.5-256 | 4 | 98.8 (≤4) |
Ampicillin | ≤0.25-128 | 4 | 93.8 (≤8) |
Teicoplanin | ≤0.03-16 | 0.25 | 98.8 (≤8) |
Ciprofloxacin | ≤0.12->64 | 16 | 75.0 (≤1) |
Quinupristin-dalfopristin | 0.25-32 | 4 | 47.5 (≤1) |
Linezolid | 1-4 | 2 | 98.8 (≤2) |
Daptomycin | 0.03-8 | 4 | (NA) |
NA, NCCLS published breakpoints unavailable for interpretation (19).